Background-Homocysteine is a sulfur amino acid whose plasma concentration has been associated with the risk of cardiovascular diseases, neural tube defects, and loss of cognitive function in epidemiological studies. 
H omocysteine is a nonprotein-forming sulfur amino acid produced during the catabolism of methionine. Its concentration is tightly regulated and kept at low levels through catabolism by either remethylation or transsulfuration. The small amount of homocysteine found in plasma is the result of a cellular export mechanism that complements the remethylation and transsulfuration pathways in maintaining low intracellular concentration of this potentially cytotoxic and pro-oxidant amino acid. [1] [2] [3] Plasma homocysteine levels are influenced by genetic and environmental factors, such as age, sex, smoking status, intake of folate, and intake of B vitamins. Homocysteine concentration has been epidemiologically correlated with the risk of cardiovascular diseases, 4, 5 neural tube defects, 6 and loss of cognitive functions. 7 
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Despite heritability estimates ranging from 25% to 44%, 8, 9 relatively little is known of the genetic determinants of homocysteine levels. Linkage scans have revealed linkage signals at 11q23, 12q14, 13q31, and 16q12, although these remain unvalidated to date. 8, 9 Rare homozygous defects in genes encoding for enzymes of homocysteine metabolism (ie, CBS and MTHFR) lead to markedly increased homocysteine concentration and premature occlusive vascular disease. 1 However, few common polymorphisms have been unequivocally associated with homocysteine concentration. Among these, the strongest is the MTHFR single-nucleotide polymorphism (SNP) rs1801133 (C677T) correlated with reduced enzymatic activity and higher homocysteine levels. 10 MTHFR encodes the enzyme methylenetetrahydrofolate reductase, which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine by methionine synthase. Along with MTHFR, genetic variations at loci such as CBS, 11, 12 (cystathionine ␤synthase), MTR 13 (5-methyltetrahydrofolate-homocysteine methyltransferase), and MTRR 14 (5-methyltetrahydrofolatehomocysteine methyltransferase reductase) have also been reported to influence homocysteine concentration.
In an effort to identify new genetic variants influencing homocysteine concentration, we performed a genome-wide association analysis, testing 336 469 SNPs in 13 974 healthy women. Because homocysteine is a direct intermediary of metabolic pathways, this offers the possibility of improving our knowledge not only of homocysteine metabolism but also of the genetic architecture of metabolic traits in general. Furthermore, finding novel genetic associations with homocysteine concentration will provide opportunities to better delineate the role of homocysteine in health and disease.
Methods

Women's Genome Health Study Participants
The study population derived from the Women's Genome Health Study (WGHS). 15 Briefly, participants in the WGHS include American women from the Women's Health Study with no prior history of cardiovascular disease, cancer, or other major chronic illness who also provided a baseline blood sample at the time of study enrollment from which genomic DNA was extracted. 16 Individuals with prevalent diabetes were excluded from analysis. The study was approved by the institutional review board of the Brigham and Women's Hospital.
EDTA blood samples were obtained at the time of enrollment and stored in vapor phase liquid nitrogen (Ϫ170°C). The concentration of homocysteine was determined using an enzymatic assay on the Hitachi 917 analyzer (Roche Diagnostics) using reagents and calibrators from Catch, Inc. 17 The sensitivity of the homocysteine assay is 0.24 mol/L, and its coefficient of variation is 1.8% at 15.6 mol/L. Participants also completed a 131-item semiquantitative food frequency questionnaire at baseline 18 from which intake of folate, vitamin B 6 , and vitamin B 12 was evaluated. Nutrient intake assessments made by use of the food frequency questionnaire used have been previously shown to be valid and reliable, 19, 20 with correlation coefficients of 0.49 to 0.55 for estimated folate and B-vitamin intake with this questionnaire method compared with measured plasma concentrations in apparently healthy female professionals similar to our study participants. 21, 22 Genotyping DNA samples were genotyped with the Infinium II technology from Illumina. Either the HumanHap300 Duo-Plus chip or the combination of the HumanHap300 Duo and I-Select chips was used. In either case, the custom content was identical and consisted of candidate SNPs chosen without regard to allele frequency to increase coverage of genetic variation with impact on biological function including metabolism, inflammation, or cardiovascular diseases. Specifically, all University of California Santa Cruz coding nonsynonymous SNPs, University of California Santa Cruz splice-site SNPs, University of California Santa Cruz SNPs with phenotype annotation, and SNPs from targeted cardiovascular diseases, diabetes, venous thromboembolism, blood pressure, and inflammation candidate genes were selected.
Furthermore SNPs with call rates Ͻ90% were excluded from further analysis. Likewise, all samples with percentage of missing genotypes higher than 2% were removed. Among retained samples, SNPs were further evaluated for deviation from Hardy-Weinberg equilibrium using an exact method 23 and were excluded when the probability value was lower than 10 Ϫ5 . Samples were further validated by comparison of genotypes at 44 SNPs that had been previously ascertained using alternative technologies. SNPs with minor allele frequency Ͼ1% in whites were used for analysis. After quality control, 307 805 HumanHap300 Duo SNPs and 28 664 custom content SNPs were left, for a total of 336 469 SNPs with a mean call rate of 99.6%.
Population Stratification
Because population stratification can result in inflated type I error in genome-wide association analysis, a principal component analysis using 1443 ancestry informative SNPs was performed using PLINK 24 to confirm self-reported ancestry. Briefly, these SNPs were chosen based on Fst Ͼ0.4 in HapMap populations (YRB, CEU, CHBϩJPT) and inter-SNP distance at least 500 kb to minimize linkage disequilibrium. Different ethnic groups were clearly distinguished with the 2 first components. On the basis of this analysis, 55 participants were excluded from further evaluation as they did not cluster with other whites, leaving 13 974 for the current study population. Two additional steps were taken to rule out the possibility that residual stratification within whites was responsible for the associations observed. First, association analysis was done with correction by genomic control. Second, a principal component analysis 25 was performed in previously identified whites (only) using 64 221 SNPs chosen to have pairwise linkage disequilibrium lower than r 2 ϭ0.2. The first 10 components were then used as covariates in the association analysis. As adjustment by these covariates did not change the conclusions, we present analysis among white participants without further correction for sub-white ancestry.
Association Analysis
To identify common genetic variants influencing homocysteine levels, we first attempted to discover which loci significantly contributed to homocysteine concentration. Log-transformed plasma concentration of homocysteine was adjusted for age, body mass index, smoking status, hormone replacement therapy use, folate intake, vitamin B 6 intake, and vitamin B 12 intake using a linear regression model in R. These covariates were chosen as they are potential environmental confounders of homocysteine levels, based on available literature. 26 -29 This was done to reduce the impact of clinical covariates on homocysteine variance. The adjusted homocysteine values were then tested for association with SNP genotypes by linear regression in PLINK, 24 assuming an additive contribution of each minor allele. ␤ coefficients of ln-transformed adjusted homocysteine values are given using the major allele as the reference allele (major and minor alleles are presented in supplemental Table  I ). A conservative probability value cutoff of 5ϫ10 Ϫ8 was used to correct for the maximum of 1 000 000 independent statistical tests thought to correspond to all the common genetic variation of the human genome. 30 Once any locus with genome-wide significance was identified, a forward selection linear multiple regression model was used to further define the extent of the genetic association. Briefly, all genotyped SNPs within 100 kb of a SNP with genome-wide association (ie, PϽ5ϫ10 Ϫ8 ) and passing quality control requirements were tested for possible incorporation into a multiple regression model. In stepwise fashion, a SNP was added to the model if it had the smallest probability value among all the SNPs not yet included in the model and if it had a probability value was lower than 5ϫ10 Ϫ8 . SNPs selected by this algorithm were also used in haplotype analysis using WHAP, 24 as implemented in PLINK. 24 
PROCARDIS Validation Sample
A subset of 840 postinfarction patients participating in the PROCARDIS study for whom homocysteine data were available was used for replication of findings in the WGHS. Detailed descriptions of the PROCARDIS population can be found elsewhere. 31, 32 In brief, cases included in the present report had a diagnosis of myocardial infarction at or before the age of 65 years and reported having European ancestry. Recruitment was carried out in Germany, Italy, Sweden, and the United Kingdom. The PROCARDIS protocol was approved by the ethics committees of the participating institutions, and all subjects gave written informed consent.
DNA was extracted and quantified as described. 31 Genotyping of a genome-wide set of 1 054 559 SNPs was performed using the Illumina Infinium II Human 1M bead chip at 2 national centers (Centre National de Génotypage, Paris, France and the SNP Technology Platform, Uppsala, Sweden). Subjects with % genotype calls Ͻ95% were excluded from further analysis as were male samples with significant X-chromosomal heterozygosity and samples with a possible population bias, as indicated from the identity by state cluster analysis. Also, when relatedness between subjects was suspected (up to 2nd degree relationships), 1 individual from the pair was removed.
EDTA blood samples were obtained in the fasting state using EDTA tubes supplemented with 4 g/L sodium fluoride as an inhibitor of erythrocyte metabolism. Total homocysteine (free and protein bound) concentration was determined immediately after thawing frozen plasma samples which had been stored at Ϫ80°C by fluorescence high-performance liquid chromatography using reagents and calibrators from Chromsystems (Munich, Germany). Isocratic reversedphase chromatography was performed on a Kontron (Neufahrn, Germany) liquid chromatograph interfaced with a model RF-535 fluorescence detector (Shimadzu, Kyoto, Japan) by using excitation and emission wavelengths of 385 and 515 nm, respectively. The coefficients of variation within and between days for the assay were Յ4.8%.
Association analysis in the validation sample was performed on log-transformed plasma concentration of homocysteine, using a linear regression model that adjusted for age, sex, body mass index, smoking status, and country of origin. Other linear models used included either of the MTHFR rs1801133 and MTHFR rs17350396 SNPs or both the rs1801133 and rs17350396 SNPs. For the analysis of sex-specific SNP-homocysteine associations, a general linear model was used comparing the main effects of SNPs on homocysteine adjusted for age, body mass index, smoking status, and country of origin within gender subgroups. Statistical analyses were performed in SPSS 16.0 for Windows.
Results
Clinical characteristics of the 13 974 healthy women in the WGHS sample are provided in Table 1 . Results of the genome-wide association analysis of log-transformed adjusted homocysteine concentration are presented in Table 2 . Twenty-nine SNPs at 6 different loci-MTHFR, CPS1, MUT, NOX4, DPEP1 and CBS-had association probability values lower than our previously defined genome-wide significance threshold of 5ϫ10 Ϫ8 : 15 SNPs at the MTHFR locus; 1 SNP at the CPS1 locus; 1 SNP at the MUT locus; 6 SNPs at the NOX4 locus; 3 SNPs at the DPEP1 locus; 1 SNP at the CBS locus. Genetic context of all these loci is presented in Figure  1 along with the Ϫlog 10 transformed probability values. In addition, 8 SNPs had association probability values just above this threshold level (between 10 Ϫ6 and 5ϫ10 Ϫ8 ), including the AKAP13 SNP rs2061821 on chromosome 15q25.3 (the remaining 7 SNPs were in the vicinity of 1 of the 6 previously identified loci). Among these SNPs, only rs4267943 (MUT; 6p12.3) deviated from Hardy-Weinberg equilibrium (Pϭ0.00006), but visual inspection of the raw genotyping signal for this SNP did not reveal any obvious artifact. Furthermore, other SNPs at this locus (rs2501976, rs6458690, and rs9473558; Table 2 ) did not deviate from Hardy-Weinberg equilibrium while being significantly associated with homocysteine level (probability values ranging from 2.1ϫ10 Ϫ7 to 5.2ϫ10 Ϫ8 ) and in linkage disequilibrium with rs4267943 (r 2 Ͼ 0.95 for all 3 pairwise comparisons). To further define the extent of genetic associations at the 6 loci with association probability value lower than 5ϫ10
Ϫ8 , we applied a forward model selection algorithm to each of them to identify SNPs nonredundantly associated with homocysteine. Briefly, 97 SNPs at MTHFR, 26 at CPS1, 20 at MUT, 32 at NOX4, 35 at DPEP1, and 34 at CBS were initially assessed for possible inclusion in a multiple linear regression model. Using a probability value cutoff of 5ϫ10 Ϫ8 , 7 SNPs were selected, representing the lead SNP at each of the 6 loci considered plus 1 SNP (rs17350396) at the MTHFR locus (Table 3) . Interestingly, this later SNP (rs17350396; MTHFR) was marginally significant in univariable analysis (Pϭ0.008), illustrating that its inclusion in the model and significant association are conditional on the genotypes at rs1801133 (MTHFR). Multiple regression ␤ coefficients and probability values of the 7 SNPs selected are shown in Table 3 . Illustrated in Figure 2 are the quantile-quantile plots of association probability values before and after adjusting homocysteine concentration for the combined effect of these 7 SNPs. Among these SNPs, only rs1801133 (MTHFR) showed evidence (Pϭ0.002) for nonadditive effects of the minor allele as judged by a likelihood ratio test comparing the additive regression model to an alternative genotype model with an additional degree of freedom. Specifically, the association tended toward a recessive genetic model, with mean log-transformed adjusted homocysteine values of Ϫ0.023 (nϭ6246) for major allele homozygotes, 0.011 (nϭ6109) for heterozygotes and 0.087 (nϭ1619) for minor allele homozygotes. However, according to the Bayes Information Criteria, the additive model still provided the best fit to the data as compared to purely recessive or dominant models. Importantly, use of a 2 degrees of freedom model did not change the result of the model selection algorithm and the genetic effect is therefore assumed to be additive for the remainder of this report. No gene-gene interaction was observed between any of the model selected SNPs. The 2 SNPs at the MTHFR locus selected by our algorithm were also used in haplotype analysis ( Table 4 ). The estimate of the proportion of variance attributable to haplotypes, as well as their regression coefficients, is consistent with the linear model of these same SNPs, reinforcing the adequacy of a multiple regression model to explain the association (as compared to the haplotype analysis). Linkage disequilibrium between these 2 MTHFR SNPs was 0.097 for r 2 and 0.978 for DЈ. The 2 SNPs at MTHFR collectively explained 1.3% of the total variance in homocysteine concentration, whereas the CPS1 SNP (rs7422339) explained 0.3%, the MUT SNP (rs4267943) 0.3%, the NOX4 SNP (rs11018622) 0.3%, the DPEP1 SNP (rs1126464) 0.3%, and the CBS SNP (rs6586282) 0.2%. In comparison, clinical covariates accounted for 8.7% of the variance (Table 5) , and together the candidate loci and the clinical variables accounted for 11.3% of total variance. Replication of the model selected SNPs was attempted in the PROCARDIS sample (see Table 1 for clinical characteristics of PROCARDIS participants). First, the 2 MTHFR SNPs, rs1801133 and rs17350396, were included in a multiple regression linear model that used homocysteine concentration as the dependant variable. Both SNPs were significantly associated with 2-sided probability values of 0.0001 (␤ϭ0.15) and 0.02 (␤ϭ0.09), respectively (and consistent direction of effect). Of note, when each SNP was included All analyses were performed using adjusted log-transformed homocysteine values (see text for details). MAF indicates minor allele frequency; HW, deviation from Hardy-Weinberg equilibrium P value; and CNS, coding nonsynonymous SNP.
*SNPs with P values less than 5ϫ10
Ϫ8
.
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separately in the linear model, only rs1801133 was associated (Pϭ0.0001) whereas rs17350396 was nonsignificant (Pϭ0.433). Because the DPEP1 SNP rs1126464 did not pass genotyping quality control in the PROCARDIS sample, we tested for association with rs460879, the second most significant SNP at the DPEP1 locus in WGHS and the SNP with the strongest linkage disequilibrium based on D' (Pϭ3.8ϫ10 Ϫ12 ; DЈϭ0.99 and r 2 ϭ0.25 between rs1126464 and rs460879). The association probability value was 0.001 (␤ϭ0.12), with consistent direction of effect. The CBS SNP rs6586282 was also replicated with a probability value of 0.02 (␤ϭϪ0.07), again with consistent direction of effect. Finally, although the CPS1 SNP rs7422339 was nonsignificant when men (nϭ658) and women (nϭ161) were considered together, the association was significant in the women considered on their own (Pϭ0.009; ␤ϭ0.2; direction of effect consistent) with a sex-SNP interaction probability value of 0.0003. No other sex interaction was noted. Associations with the MUT SNP rs4267943 and NOX4 SNP rs11018628 were nonsignificant (PϾ0.05).
Discussion
Four loci-MTHFR, CBS, DPEP1, and CPS1-have been identified and confirmed in this report for association with homocysteine levels, with the CPS1 association being sexspecific. Although genetic variants of MTHFR and CBS are known to influence homocysteine metabolism, the other associations are novel. DPEP1 (dipeptidase 1) is a kidney membrane enzyme that is highly expressed in the proximal convoluted tubules. 35 It hydrolyzes a variety of dipeptides and Ϫ8 . Also shown is the genetic distance in cM from the lowest probability value SNP (light gray line) along with the position of recombination hotspots (light gray vertical bars). Recombination rates and hotspots are based on HapMap data, as described by McVean et al 33 and Winckler et al 34 .
is implicated in renal metabolism of glutathione and its conjugates, such as leukotrienes. 36 Because DPEP1 deficiency leads to increased urinary excretion of cysteine, 37,38 a precursor of homocysteine, we hypothesize that the association between the DPEP1 coding nonsynonymous (E351Q) SNP rs1126464 and homocysteine concentration could be the result of changes in the renal handling of amino acids. Although DPEP1 offers a clear hypothesis for the observed genetic association, the high level of linkage disequilibrium in this region precludes the exclusion of other genes as mechanistically linked to homocysteine metabolism ( Figure 1E ).
Carbamoylphosphate synthetase I (CPS1) is a nuclear encoded mitochondrial matrix enzyme that catalyzes the first and rate-limiting step of the hepatic urea cycle. The hepatic urea cycle is responsible for the elimination of ammonia in the form of urea as well as the synthesis of arginine, a precursor of the potent vasodilatator nitric oxide. CPS1 synthesizes carbamoylphosphate from bicarbonate, ATP and ammonia using a cofactor N-acetylglutamate. Its genetic deficiency results in a rare autosomal recessive disease characterized by episodes of hyperammonemia in the neonatal period, with elevated plasma glutamine and low or absent citrulline. 39 The CPS1 SNP rs7422339 associated with homocysteine in a sex-specific manner in our study encodes the substitution of asparagine for threonine (T1405N) in the region critical for N-acetyl-glutamate binding and results in 20% to 30% higher enzymatic activity. 40 This variation has been shown to influence nitric oxide metabolite concentrations and vasodilation after agonist stimulation. 41 Furthermore, the same variant has been associated with the risk of pulmonary hypertension in the newborn 42 as well as the risk of veno-occlusive disease after bone marrow transplantation. 40, 43 Interestingly, nitrous oxide irreversibly inactivates the cytosolic enzyme methionine synthase by oxidizing enzyme-bound vitamin B 12 . 44, 45 Methionine synthase is a vitamin B 12 dependant enzyme that catalyzes the synthesis of methionine and methyltetrahydrofolate from homocysteine and tetrahydrofolate, the entry point of homocysteine into the remethylation pathway. Consistent with this pathway, humans and laboratory animals subjected to nitrous oxide have elevated levels of plasma homocysteine. 46 -50 The MUT and NOX4 loci were associated with homocysteine levels in the WGHS sample, but these associations were not replicated in the PROCARDIS sample. Although rs4267943 is a nonsynonymous coding SNP (G63R) in the gene CENPQ (centromere protein Q), the most likely candidate gene for its association with homocysteine is MUT. CENPQ itself encodes for a protein responsible for proper kinetochore function and mitotic progression. 51 Although we cannot exclude an effect on CENPQ, we note that rs4267943 is Ϸ10 kb upstream of the MUT transcription start site and is in high linkage disequilibrium (r 2 Ͼ0.95) with other MUT genetic variants, including a nonsynonymous coding SNP rs9473558 (R532H; Pϭ2.1ϫ10 Ϫ7 ). MUT encodes for the mitochondrial enzyme methylmalonyl-Coa mutase and as such, catalyzes the isomeration of methylmalonyl-Coa into succinyl-Coa. Although its catalytic activity is hardly related to homocysteine, MUT has frequently been associated with homocysteine metabolism because it is 1 of 3 vitamin B 12 dependant enzymes, along with methionine synthase and leucine aminomutase. 52 Moreover, based on the observation All analyses were performed using adjusted log-transformed homocysteine values (see text for details). MAF indicates minor allele frequency; HW, deviation from Hardy-Weinberg equilibrium P value; and CNS, coding non-synonymous SNP. that patients with vitamin B 12 deficiency but high blood folate have higher plasma methylmalonic acid concentration (than low vitamin B 12 , low folate patients), it has been proposed that the enzymatic activity of methionine synthase interferes with the activity of methylmalonyl-Coa mutase through diversion of vitamin B 12 from the mitochondrion to the cytosol. 53 The genetic association observed in WGHS (but not in PROCARDIS) reinforces this hypothesis by suggesting that methylmalonyl-Coa mutase activity itself could impact on methionine synthase activity (and therefore homocysteine concentration) through a similar mechanism.
NOX4 encodes for a recently described reduced nicotinamide-adenine dinucleotide phosphate oxidase that is highly expressed in the kidney. 54 As such, it catalyzes the formation of the free-radical superoxide using O 2 as an electron acceptor and reduced nicotinamide-adenine dinucleotide phosphate as the donor. The exact role of NOX4 in normal physiology is yet to be determined, but NOX4 expression has recently been correlated with increased albuminuria in adiponectin deficient rats. 55 For these reasons, the most compelling explanation for the observed genetic association between the intronic NOX4 SNP rs11018628 and plasma homocysteine concentration is regulation of renal handling of homocysteine by NOX4. This association, however, requires further validation given its failure to replicate in the PROCARDIS sample.
Despite the confirmatory nature of the MTHFR association, we also identified a novel MTHFR variant (rs17350396) that nonredundantly influenced homocysteine concentration after taking into account the effect of the known MTHFR SNP rs1801133 (C677T; A222V), paving the way for more complete assessment of the impact of this locus on human disease. Although genetic variants of CBS have previously been reported to influence homocysteine concentration, 11, 12 the intronic CBS SNP rs6586282 described in this report is either in unremarkable or unknown linkage disequilibrium with these other variations. CBS catalyzes the first step in the transsulfuration pathway of homocysteine catabolism. 1 Our study has potential limitations. First, even though all associations in WGHS had probability value lower than the conservative 5ϫ10 Ϫ8 threshold and care was taken to correct for the potential effect of population stratification, we were not able to confirm the MUT and NOX4 findings in the separate PROCARDIS sample. This might be the result of the much smaller size of the PROCARDIS sample. For instance, the power to replicate the MUT association at a nominal level of significance of 0.05 in PROCARDIS was 27% whereas it was 29% for NOX4. Second, because of the nature of the WGHS and PROCARDIS samples, extension of these associations in nonwhite populations will require further testing, even if we have no a priori reason to believe there should be heterogeneity. Third, the overall variance explained by these associations (2.6%) is small as compared with heritability estimates of homocysteine levels 8, 9 (ranging from 25% to 44%), suggesting that many other genetic variants remain to be discovered. Fourth, the observation of a significant sexinteraction for the CPS1 association hints at different genetic architectures of homocysteine levels in men and women. Our study might therefore have missed male-specific associations. Finally, although many of these novel associations offer tantalizing hypotheses regarding homocysteine metabolism, further biological experiments are needed to define the processes underlying them.
In this report, we found associations of homocysteine with genetic variation at the MTHFR, CPS1, MUT, NOX4, DPEP1, and CBS loci, with independent replication of the MTHFR, CPS1, DPEP1, and CBS findings. Although associations at the MTHFR and CBS loci extend previous work done on the genetic basis of homocysteine plasma concentration, our other findings are entirely novel. It will be of considerable interest to study these associations in nonwhite populations, as well as test these polymorphisms for association with cardiovascular diseases, neural tube defects and cognitive decline. These hypotheses generating genetic observations pave the way for further biological studies of homocysteine in the pathophysiology of these diseases. Furthermore, these genetic observations provide new insights into the biochemical pathways involved in homocysteine metabolism. 
